University of Alabama at Birmingham, 1998, PhD
Shanghai Medical University, China, 1990, MD
The focus of Dr. Fang's laboratory research is on the genomics and combinatorial genetics/epigenetics of human neoplasia. Combining classical genetic approaches of mapping, karyotyping, fluorescence in situ hybridization, single-gene mutation analysis, bisulfite sequencing, and functional genetics with new genomic tools including microarray, comparative genome hybridization, and next-generation sequencing, we aim to identify genetic and epigenetic aberrations in cancer that are prognostically significant and may serve as actionable biomarkers for treatment decision making for individual patients. Dr. Fang's research is currently supported by funding from the National Institute of Health and the HOPE Foundation.
Dr. Fang's current clinical service is as Director of the Cytogenetics Department at the Seattle Cancer Care Alliance, responsible for the clinical operation and daily sign-out of cytogenetic/molecular testing on adult and pediatric patients undergoing hematopoietic stem cell transplantation as well as other cancer patients. She was Director of Human Molecular Genetics laboratory and Section Chief for Oncology Cytogenetic Testing while at the University of Connecticut Health Center. She served on the Genetics Review Panel of Center for Disease Control, Nominating Committee of the Association for Molecular Pathology, Lea's Foundation Hematology Advisory Committee, University of Connecticut Translational Genomics Core Advisory Committee, and is currently the Cytogenetics Subcommittee co-Chair of SWOG Leukemia Committee since 2009 and the Chair of the Publication and Communication Committee of the Association for Molecular Pathology (AMP) and a member of the Board of Directors of AMP.
Dr. Fang’s current studies focus on two diseases as representation of solid tumor and hematological malignancy. As part of a UW/FHCRC project grant for understanding the mechanism and markers for prostate cancer metastases, we genomically characterize the disseminated tumor cells (DTC) of prostate cancer, looking at correlates to progression and biological functions to explore the stem cell aspects of DTC and the role of DTC in tumor dormancy. We also use high-throughput epigenetic tools to identify methylation markers important to distinguish indolent versus aggressive prostate cancer. For the study of acute myeloid leukemia (AML), we compare the global methylation profiling of good- and poor-outcome AML patients, especially those with normal cytogenetics, to identify differentially methylated genomic regions that will predict outcome and therapeutic response. Integrated studies of epigenetic and genomic/expression profiling, as well as functional pathway analyses, are important to help gain true insight into the pathophysiology of human cancer.